Carl KestensDec 21, 202114 min readTHE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART III: AN INTRODUCTION TO INKMUNEINTRODUCTION As an immunotherapy drug candidate, INKmune seems by far the most commercially sustainable, undervalued that I am aware of....
Carl KestensDec 17, 202111 min readTHE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART IIDrug XPro of INmune Bio has limitless potential in neurodegenerative diseases such as Alzheimers, ALS, MS, Huntington's, Parkinson's, ...